Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Meyer, Brett
NCT02864953 / 2017-004854-41: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction	Terminated	3	535	Europe, Canada, Japan, US, RoW	BIIB093, glibenclamide, glibenclamide intravenous (IV), glyburide, CIRARA, Placebo	Remedy Pharmaceuticals, Inc.	Brain Edema, Stroke, Acute	08/23	08/23
MOST, NCT03735979: Multi-arm Optimization of Stroke Thrombolysis	Completed	3	514	US	Argatroban, Eptifibatide, Placebo	Washington University School of Medicine, National Institute of Neurological Disorders and Stroke (NINDS)	Acute Ischemic Stroke	12/23	10/24
FASTEST, NCT03496883: Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial	Recruiting	3	860	Europe, Canada, Japan, US	Recombinant Activated Factor VII (rFVIIa), NovoSeven, NiaStase, Placebo	Joseph Broderick, MD, Novo Nordisk A/S, National Institute of Neurological Disorders and Stroke (NINDS)	Intracerebral Hemorrhage	01/28	01/28
DISCOVERY, NCT04916210: Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY	Recruiting	N/A	8000	US		Massachusetts General Hospital, National Institute of Neurological Disorders and Stroke (NINDS)	Ischemic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Dementia, Vascular, Mild Cognitive Impairment, Vascular Cognitive Impairment	11/25	11/25